World Congress of Asthma - October 3-6, 2018, Tokyo, Japan / Abstract
Following the request from several participants we have the pleasure and honor to inform you that the deadline for submission of abstracts has been extended until June 30, 2018. The early bird fee is therefore also extended until June 30, 2018.
Deadline to submit an abstract for the XXIV World Congress of Asthma in Tokyo, Japan, October 3-6, 2018, expires on Friday, June 8
The deadline to electronically submit an abstract for the XXIV World Congress of Asthma in Tokyo, Japan, October 3-6, 2018, expires on Friday, June 8, so you still have the opportunity to take advantage of the Early Bird Registration fee.
To Submit your Abstract please click HERE
To Register please click HERE
Your data privacy and communication preferences are a top priority for us so in order to comply with GDPR consent requirements, we need to know that you would still like to receive content in relation to Global Asthma Association - Interasma and its World Congress of Asthma.
We will only contact you with useful information in relation to and on behalf of the GAA-Interasma Board and the Organizing & Scientific Committees of WCAs.
If you prefer to be opted out of all communications, please click the Unsubscribe link below.
Asthma Research and Practice: Effect of adjusting the combination of budesonide/formoterol on the alleviation of asthma symptoms
The combination of budesonide + formoterol (BFC) offers the advantages of dose adjustment in a single inhaler according to asthma symptoms. We analyzed the relationship between asthma symptoms in terms of peak expiratory flow (PEF) and dose adjustment by the patient.
Twenty-eight patients with asthma who used BFC for alleviation of their symptoms (12 men, 16 women; 60 years old) were instructed that the inhaled BFC dose could be increased to a maximum of 8 inhalations per day according to symptom severity. Patients measured and recorded PEF every morning and evening in their asthma diary along with their symptoms and the dose of drugs taken.
Sixteen of the 28 patients increased their dose for asthma symptoms. The time to recovery from the asthma symptoms was significantly shorter when cough was the only symptom present compared with dyspnea or wheeze (1.4 vs. 5.3 or 6.6 days, p < 0.05) and when they had only one symptom compared with two or three symptoms (1.3 vs. 5.7 or 10.5, p < 0.01). The relationship between PEF (% of personal best) when the dose was increased (Y) and the days for the increased dose to achieve a PEF greater than PEF in the symptom-free state (X) was determined to be Y = − 0.591X + 89.2 (r2 = 0.299, p < 0.001).
As a guide for increasing the BFC dose when patients with mild asthma have asthma symptoms, the dose should be increased when cough is present or PEF is decreased to 88.9% (i.e., X = 0.5).
The following new article have just been published in Asthma Research and Practice: Associations of physical activity with childhood asthma, a population study based on the WHO - health behaviour in school-aged children survey
Lene Lochte, Poul Erik Petersen, Kim G. Nielsen, Anette Andersen and Thomas A. E. Platts-Mills
Asthma in paediatric populations is one of the highest public health concerns. In this study of children and adolescents, we hypothesized that low levels of physical activity (PA) would show associations with asthma that vary by asthma outcome. The objective was to assess whether PA was associated with ever asthma and/or current asthma.
Analyses were based on 4824 Danish schoolchildren aged 11–15 years old (48.7% boys) participating in the HBSC survey. The study variables were (1) physician-diagnosed asthma (ever asthma) and (2) physician-diagnosed asthma plus wheezing and/or physician or hospital consultation for wheezing (current asthma). Associations with PA by gender were analysed with multivariate logistic regression using the “variance covariance (vce) cluster” method.
The prevalence of ever asthma was 14.3% (boys) and 12.8% (girls), and that of current asthma was 6.8% (boys) and 7.0% (girls). Boys with current asthma showed important differences in low and high PA. We found inverse associations between low PA and ever asthma, odds ratio [95% confidence interval] male: .55 [.30; .99] and female: .47 [.24; .93], and current asthma, male: .27 [.12; .60] (P linear trend = .007) and female: .32 [.11; .94].
The lowest activity levels showed significant inverse associations with asthma, regardless of the definition. For boys, the more stringent (current asthma) of the two paediatric asthma definitions revealed a significant trend with PA, and the direction of associations shifted to positive as weekly PA increased.
New Article From Asthma Research and Practice: Clinical characteristics and comorbidities of elderly asthmatics who attend allergy clinics
To date, few studies have focused on the clinical and allergic characteristics of asthma in the elderly, defined as asthma in people aged 60 or over. Thus, we propose to identify and study the clinical and allergic characteristics and comorbidities of patients with asthma among the elderly.
A retrospective, observational, descriptive study was developed in five clinics and hospitals in Argentina. Allergy Physicians analyzed their patients’ medical records in 2014 and included those adults over the age of 60, who had been diagnosed with asthma according to the GINA guidelines. Clinical and allergic characteristics were analyzed.
A total of 152 patients diagnosed with asthma, of whom 73% were women and 11% ex-smokers, were included in this study, with a mean age of 66 years. Only 10.5% of the participants had onset asthma past the age of 60. Regarding asthma severity, 74.3% were diagnosed with moderate persistent asthma, and 7.2% with severe persistent asthma. Eighty-four percent of the patients were treated with an inhaled corticosteroid (ICS) along with a long-acting β 2-adrenergic agent (LABA). More than half of the patients had two or more comorbidities simultaneously. Allergic comorbidities were the most frequent comorbidities, followed by arterial hypertension. Among allergic comorbidities, most patients presented allergies at the nasal level. There were no significant differences between the subpopulations of patients with late-onset asthma (LOA) and asthma with onset before the age of 60, i.e. early onset asthma (EOA) in most of their clinical characteristics. However, it was observed that EOA accounted for a higher percentage of patients with nasal allergies as compared to LOA (71% vs 46%, p < 0.05).It is worth mentioning that almost half of the patients with LOA had allergies at the nasal level.
These results may provide a better understanding of the clinical characteristics of asthma in the elderly in Argentina, thus, enabling the development of future therapeutic strategies and a better quality of life for our elderly asthma patients.
WCA 2018 - Abstract Submission
Submission Deadline June 08, 2018
Rationale: A brief statement of purpose of the study and the hypothesis to be tested.
Methods: Summarize the predictors and outcomes analyzed, as well as the methods used.
For abstracts reporting clinical research, a sentence or phrase presenting the most important selection criteria for subjects should be included.
Results: Provide a summary of the results including quantitative data, presented in sufficient
detail with statistical analysis when possible to support the conclusions.
Conclusions: Summarize the impact and significance of the findings. It is not sufficient to
state, “The results will be discussed,” or “other data will be presented,” etc.
Be sure to use the words “Rationale, Methods, Results and Conclusions” in the body of your abstract to indicate the start of each new section. See the Sample Abstract included in this document. Author information should not be included in the body of the abstract.
The maximum length of an abstract submitted is 250 words. Use of the words “Rationale, Methods, Results and Conclusions” as described above will not count towards the 250 word total.
Capitalize only the first letter of each word of the title.
The use of standard abbreviations is desirable (i.e., rbc, kg, mg). A special or unusual abbreviation should be placed in parentheses after the first appearance of the full word which it represents. Do not use periods after abbreviations or initials. Numerals rather than words should indicate numbers, except to begin sentences.
Non-proprietary (generic) names are preferred and should be used in the title of the abstract. Generic drug names are not capitalized in the body of the abstract. If a proprietary drug name is used in the body of the abstract, the first letter is capitalized.
You may use your word processor’s capabilities for bold, underline, italic, subscript and superscript, or use the tools provided when entering your abstract. Bold the words Rationale, Methods, Results and Conclusions used to separate one section of the abstract from another. Text that will be in italics in published form (e.g., genus, species) may be formatted as italics.
Abstracts will be graded by several reviewers on the following criteria; Clinical or basic science significance, Methodology and as an Overall submission. Reviewers are also asked to flag abstracts that involve research on human or animal subjects if the corresponding approvals are missing.
World Congress of Asthma 2018 - Scientific Program Committee's Message
Significant achievements have been accomplished in the last few years to better understanding what asthma is, how it should be assessed in regards to control and severity and what its optimal therapy is. Unfortunately, these improvements in our understanding of the disease have not always translated into better asthma management.
The 2018 World Congress on Asthma in Tokyo will review the key findings from recent research on both adult and pediatric Asthma and how knowledge translation methods have evolved to better integrate research findings into care.
The origins and determinants of Asthma, triggers and inducers, the new insight gained on the role of allergy, environmental and biodiversity changes, workplace hazards, respiratory infections and various aspects of assessment of the disease are among the topics that will be addressed by world experts. The role of phenotyping/endotyping Asthma, particularly when severe, and new therapeutic current and future advances will be covered.
A significant part of the meeting will be devoted to practical workshops on asthma testing and treatment delivery, as well as the integration of practice tools into day-to-day care. Sessions will discuss how to optimize the multidisciplinary approach to asthma management.
We and the members of the scientific advisory board are confident that the impressive program of WCA-2018 will be of interest to all those involved in research and care of asthma.
G. Walter Canonica Lawrence DuBuske Louis-Philippe Boulet Fulvio Braido
New article published in Asthma Research and Practice: Single nucleotide polymorphisms in asthma candidate genes TBXA2R, ADAM33 FCER1B and ORMDL3 in Pakistani asthmatics a case control study
|Nusrat Saba, Osman Yusuf, Sadia Rehman, Saeeda Munir, Amna Noor, Muhammad Saqlain, Atika Mansoor and Ghazala Kaukab Raja|
|Asthma Research and Practice 2018, 4:4 | Published on: 22 March 2018|
Genetic variations in different loci and genes are important in asthma pathogenesis. There is much importance of various immunological pathways in the IgE secretion regulation. Alterations in any main part of these pathways can increase the risk of asthma development. Polymorphisms in these genetic markers can effect certain pathways which predict the asthma susceptibility. In the present study, SNPs directly or indirectly affecting the immunological process pathways are selected.
This study was conducted to determine association of 16 SNPs in 10 candidate genes with asthma in Pakistani population in 333 asthmatic cases and 220 healthy controls. Genotyping was performed using the Sequenom Mass ARRAY iPLEX platform (14 SNPs) and TaqMan assay (2 SNPs).
The minor allele at two of the SNPs showed association with protection from asthma, rs1131882 in TBXA2R gene (OR 0.73, 95% CI 0.52–1.01, P = 0.05) and rs2280091 in the ADAM33 gene (OR 0.69, 95% CI 0.50–0.97, P = 0.03). For FCER1B gene, rs2583476 the asthmatic male gender had higher TT genotype counts as compared to controls (OR = 1.86, 95% CI = 1.09–3.17, p = 0.01). In rs11650680 of ORMDL3 gene the CT genotype is more prevalent in female asthma cases in comparison with female controls (OR = 1.99, 95% CI = 1.02–3.89, p = 0.03).
This data suggests that variations at TBXA2R and ADAM33 genes are found to be associated with asthma susceptibility in Pakistan. FCER1B gene is associated with male and ORMDL3 in female asthmatics. These genetic markers can be important source of asthma risk in Pakistani population.
New Article From Asthma Research and Practice: Inhalation of hydrogen gas attenuates airway inflammation and oxidative stress in allergic asthmatic mice
Inhalation of hydrogen gas attenuates airway inflammation and oxidative stress in allergic asthmatic mice
Asthma is a worldwide common chronic airway disease that cannot be cured and results in the huge burden in public health. Oxidative stress was considered an important mechanism in the pathogenesis of asthma. Hydrogen gas been demonstrated to function as a novel antioxidant and exert therapeutic antioxidant activity in a number of diseases and the function of this nontoxic gas in asthma was unclear. The purpose of the study aims to examine the effect of inhalation hydrogen gas on the pathophysiology of a mouse model of asthma.
A murine model of ovalbumin (OVA)-induced allergic airway inflammation was used in this study. Briefly, Mice were sensitized to ovalbumin and received inhalation of 67% high concentration of hydrogen gas for 60 min once a day for 7 consecutive days after OVA or PBS challenge respectively. Lung function was assessed in the apparatus with 4 channels of biological signal system. Morphology and goblet cell hyperplasia were stained by H/E and Periodic acid-Schiff staining. Cytologic classification in the bronchial alveolar lavage fluid (BALF) was analyzed by Wright Giemsa staining. Serum, BALF and lung tissue were collected for biochemical assay. One-way analysis of variance (ANOVA) was used to determine statistical significance between groups. Multiple comparisons were made by Bonferroni’s Multiple Comparison Test by using GraphPad Prism 5 software.
Inhalation of hydrogen gas abrogated ovalbumin-induced the increase in lung resistance. Concomitantly, the asthmatic mice showed severe inflammatory infiltration and goblet cell hyperplasia which were reversed by hydrogen gas inhalation. Hydrogen gas inhalation reduced significantly the number of total cells, eosinophils and lymphocytes in BALF. Increased level of IL-4, IL-13, TNF-α and CXCL15 in the BALF and IL-4 in the serum were decreased significantly after inhalation. Hydrogen gas inhalation markedly upregulated the activity of decreased superoxide dismutase and significantly attenuated the increased level of malondialdehyde and myeloperoxidase.
Hydrogen gas inhalation improves lung function and protects established airway inflammation in the allergic asthmatic mice model which may be associated with the inhibition of oxidative stress process. This study provides a potential alternative therapeutic opportunity for the clinical management of asthma.